Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Non-Cytologic Cervical Screening Is Cost-Effective – NEJM Study

This article was originally published in The Gray Sheet

Executive Summary

Strategies such as visual inspection of the cervix or the use of human papillomavirus assays that require only one or two clinical visits are cost-effective alternatives to conventional three-visit cytology-based screening in low-resource settings, according to a study published in the Nov. 17 New England Journal of Medicine

You may also be interested in...



One-Stop Cervical Cancer Screening And Treatment May Improve Care – JAMA

The "screen-and-treat" approach to cervical cancer could stem the spread of the disease in areas with few medical resources, according to two studies published in the Nov. 2 issue of the Journal of the American Medical Association

Cervical Imaging Device Prompts FDA Panel Concern With False Positives

FDA's Obstetrics & Gynecology Devices Panel concluded May 17 that MediSpectra's pivotal studies failed to show a statistically significant benefit for the Luma cervical imager

New EU Approvals

The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with seven new products including Roche's Polivy for treating diffuse large B-cell lymphoma. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).

UsernamePublicRestriction

Register

MT022927

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel